A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Ospemifene (Osphena)

Estrogen Agonist/Antagonist class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2023-04-01
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$11.4M in CY2024 Part D spend25K claims · 8K beneficiaries · 329 plans surveyed

Lowest NADAC
$8.16/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$8.16
Across all dosage forms in distribution.
Highest NADAC
$8.16
Range is tight.
Plans with PA
38 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Ospemifene used for?

Ospemifene is a Estrogen Agonist/Antagonist medication tracked in Medicare Part D.

Is there a generic for Ospemifene?

No. Ospemifene is brand-only with no generic equivalents currently in market.

How much does my plan pay for Ospemifene?

Across 329 Part D plans, Ospemifene averages $8.16/unit (NADAC). Lowest available: $8.16/unit. Highest in distribution: $8.16/unit.

Is Ospemifene on the FDA shortage list?

No. Ospemifene is not currently on the FDA Drug Shortage Database.

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Estrogen Agonist/Antagonist3 alternatives in D1
01
Clomiphene
Brand: CLOMID
$6.64Lowest NADAC
6Generic mfrs
$1.4MCY24 Part D spend
Compare →
02
Raloxifene
Brand: Evista
$0.248Lowest NADAC
8Generic mfrs
$48.7MCY24 Part D spend
Compare →
03
Tamoxifen
Brand: SOLTAMOX
$0.139Lowest NADAC
5Generic mfrs
$16.0MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (1 approvals on file) · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.